THIS WEEK
⚡ Quick hits header
💰Money Moves
WHOOP closes $575M Series G at a $10.1B valuation — Abbott and Mayo Clinic join as strategic investors. The diagnostics convergence angle is bigger than the number. Full breakdown below. · BusinessWire →
Eli Lilly acquires Centessa Pharmaceuticals — a targeted bet on CNS and sleep-wake disorders. Signals continued Big Pharma appetite for specialized pipeline assets as GLP-1 revenue funds bolder M&A. · Eli Lilly News Release →
⌚On the Wrist
Samsung enables blood pressure monitoring for U.S. Galaxy Watch users — after years of South Korea-only availability, cuffless BPM has arrived stateside. Uses optical sensing with cuff calibration. Watch how claims language evolves — this is the post-WHOOP-reversal regulatory playbook in real time. · Samsung Newsroom →
🤖AI Watch
Microsoft Copilot's "Critique" = GPT + Claude working together — In a new feature called "Critique," Copilot's Researcher agent can now pull outputs from both OpenAI's GPT and Anthropic's Claude models for every response. · Reuters →
🏥Care Delivery
📋Policy & Payer
💊Pharma Corner
Lilly GLP-1 pill Foundayo™ (orforglipron) receives FDA approval on April 1 — the only GLP-1 pill for weight loss that can be taken any time of day without food or water and the 1st NME approved under the Commissioner's National Priority Voucher (CNPV) pilot program. Issued 50 days after filing and 294 days before the anticipated approval date! · US FDA.gov →
📡 Deep dive
WHOOP hits $10B — and the Abbott deal is the part nobody's talking about
On March 31, WHOOP closed a $575 million Series G round at a $10.1 billion valuation — nearly tripling its last reported figure. The headline investors read like a who's who of global capital: Qatar Investment Authority, Mubadala, LeBron James, Cristiano Ronaldo. But the strategically important name on that list is Abbott.
$575M
Series G raise
$10.1B
Valuation
2.5M
Members
Abbott — maker of FreeStyle Libre, the world's leading continuous glucose monitor — joining as a strategic investor is not a passive financial play. It mirrors almost exactly what happened when Dexcom invested in Oura in 2024. Within a year of that deal, Oura's ring was integrating real-time CGM data. If the same logic applies here, WHOOP's platform of physiological data (sleep, HRV, ECG, blood pressure) plus Abbott's biosensor capabilities could converge into something that looks a lot less like a fitness tracker and a lot more like a clinical-grade continuous monitoring system.
The regulatory backstory: The FDA issued WHOOP a warning letter in July 2025 over its Blood Pressure Insights feature, asserting it was an uncleared medical device. WHOOP publicly pushed back and declined to remove it. In January 2026, the FDA reversed course — allowing blood pressure insights under general wellness exemptions. That regulatory clarity almost certainly accelerated this raise. Full context in the regulatory section below.
Mayo Clinic's participation adds a second strategic layer. Clinical validation is the missing link for consumer wearable platforms trying to cross into healthcare. With Mayo in the cap table, WHOOP gains a credible pathway to study its physiological data in real patient populations — moving the platform from performance optimization into genuine preventive medicine territory.
What the valuation actually implies: At $10.1B on a reported $1.1B revenue run rate, WHOOP is not being priced as a fitness subscription business. It is being priced as a future healthcare platform integrating continuous diagnostics with clinical partnerships — a bet that has not yet fully materialized, but now has serious institutional credibility behind it.
The bottom line: This is a health data platform positioning itself at the intersection of continuous monitoring, AI-driven biomarker analysis, and clinical validation — exactly the space where the highest-value digital health companies will operate over the next decade.
Sources: BusinessWire · Fierce Biotech · TechCrunch · Medical Device Network
🔬 Regulatory radar
FDA rewrites the wellness-device boundary — what it means for your product
On January 6, 2026, FDA Commissioner Marty Makary used his CES keynote to announce updated guidance on both Clinical Decision Support (CDS) software and General Wellness products. The stated goal: move regulation at "Silicon Valley speed." The practical implications are still being absorbed by industry.
What changed for General Wellness products: The revised guidance explicitly allows non-invasive wearables estimating physiologic parameters — blood pressure, oxygen saturation, glucose-related signals — to remain outside FDA device regulation, provided they stay within wellness framing and include appropriate disclaimers. This directly reversed the stance the FDA took against WHOOP in July 2025.
Compliance watch: The expanded wellness safe harbor is real — but the labeling guardrails are strict. Any implied diagnostic or treatment claim triggers device status. If you are developing a product that estimates physiologic parameters, your marketing language now matters more than your underlying technology. Review your claims language now.
What changed for CDS software: Previously, software presenting a single clinical recommendation raised "automation bias" concerns — pushing it toward medical device classification. The 2026 update relaxes this. A single, clinically appropriate recommendation where the clinician can independently review the rationale may now fall outside device regulation. This matters enormously for AI clinical decision support tools and diagnostic copilots.
The line that still holds: High-risk AI that substitutes for clinical judgment — especially black-box tools without transparent reasoning — remains fully in regulated territory. The FDA has essentially said: more runway for tools that enhance clinician judgment, full scrutiny for tools that replace it.
Sources: STAT News · Ropes & Gray · Orrick · Nixon Law Group
💡 Maria's take
The diagnostics-wearable convergence is the most important story in digital health right now
I have spent two decades watching the gap between what technology can measure and what clinical systems will actually accept for decision-making. That gap has been the defining friction in digital health commercialization. What I am seeing now — with Abbott joining WHOOP, and Dexcom-Oura before it — is the first systematic attempt to close it from both sides simultaneously.
Diagnostics companies bring what wearables need most: clinical credibility, regulatory track records, and hospital relationships. Wearable platforms bring what diagnostics companies cannot easily build: continuous passive data, massive consumer engagement, and datasets measured in billions of hours. When these combine, the result is not a fitness tracker with clinical ambitions — it is a continuous monitoring system with consumer distribution.
For the founders and executives in my network building in this space: the question I would be asking is not "should we pursue FDA clearance?" but rather "what kind of strategic partner positions us for the next wave of these integrations?" The M&A logic is becoming clear. The clinical validation story is being written right now. If you want to talk through how this applies to your commercialization roadmap, my inbox is open.
📚 One resource worth your time - This week recommended
That's Issue #1. If a colleague would benefit from this, the best thing you can do is forward it — it takes 10 seconds and means a lot.
See you next week.
Maria Tsiper, Ph.D.
PolyOMIC Solutions · polyomicsolutions.com